

Natural Products

Short, Tin-Free Synthesis of All Three Inthomycins

Manjeet Kumar, Liam Bromhead, Zoe Anderson, Alistair Overy, and Jonathan W. Burton*^[a]

Abstract: The inthomycins are a family of structurally and biologically rich natural products isolated from *Streptomyces* species. Herein the implementation of a modular synthetic route is reported that has enabled the enantioselective synthesis of all three inthomycins. Key steps include Suzuki and Sonogashira cross-couplings and an enantioselective Kiyooka aldol reaction.

The inthomycins A–C (1–3, Figure 1), also known as the phthoxazolins, are a family of oxazole triene natural products isolated from *Streptomyces* culture that display both interesting structures and a wide range of biological activities. The isolation of inthomycin A was first reported by Ōmura in 1990^[1] who subsequently reported the isolation of inthomycins B and C in 1995.^[2] Between these dates, Zeek had reported the re-isolation of inthomycin A and the first isolation of inthomycins B and C.^[3] Inthomycin A was discovered in a screen for inhibitors of cellulose biosynthesis, however, not only does inthomycin A inhibit cellulose biosynthesis,^[1,4] but it also shows both herbici-




Figure 1. Inthomycin natural products.

[a] Dr. M. Kumar, Dr. L. Bromhead, Dr. Z. Anderson, A. Overy, Dr. J. W. Burton
Department of Chemistry, University of Oxford, Chemistry Research Laboratory
Mansfield Road, Oxford, OX1 3TA (UK)
E-mail: jonathan.burton@chem.ox.ac.uk

Supporting information and the ORCID identification number(s) for the author(s) of this article can be found under:
<https://doi.org/10.1002/chem.201803794>.

© 2018 The Authors. Published by Wiley-VCH Verlag GmbH & Co. KGaA. This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.

dal,^[4,5] and antifungal^[4] activity, and both inthomycin A^[6] and inthomycin B^[6b] inhibit prostate cancer cell growth. Very recently the cytotoxicity of inthomycin C against a range of human cancer cell lines has been investigated but the natural product showed little biological activity. However, a close analogue (23) was found to have proteasome inhibition activity.^[7] Apart from their biological significance, the structures of the inthomycins are particularly striking in that they contain a methylene interrupted oxazolyl-triene moiety including a tri-substituted alkene and a chiral allylic β -hydroxy carbonyl moiety. Moreover, the full structural motif of the inthomycins is found within a number of more complex natural products including the oxazolomycins, 16-methyloxazolomycin, curromycin A and B, and KSM 2690.

Given their wide ranging biological activities and interesting structures, the inthomycins have attracted considerable attention from the synthetic community, although their deceptively simple structures belie the challenge associated with their synthesis. To date, synthetic effort has primarily focused on inthomycin C with only one report on the enantioselective synthesis of inthomycin A and only two on the enantioselective synthesis of inthomycin B. The first synthesis of inthomycin A (1) in racemic form was disclosed by Whiting in 1999^[8] with the only enantioselective synthesis of 1 being reported by Hatakeyama in 2012^[9] who disclosed the enantioselective synthesis of inthomycins B 2 and C 3 in the same publication. In 2006 Taylor reported the first enantioselective synthesis of inthomycin C 3 and of racemic inthomycin A 1 in 2008.^[11] In 2010, Ryu reported an enantioselective synthesis of inthomycin C 3^[12] which was followed by Hale's reports on the enantioselective synthesis of 3.^[13] Very recently the Donohoe group published an enantioselective synthesis of inthomycin C 3.^[7] All of the syntheses of the inthomycins bar one,^[7] feature a Stille cross-coupling as a key step with the inherent problems associated with the toxicity and disposal of stoichiometric organotin waste. Herein we report short (9/10 steps, longest linear sequence), tin-free syntheses of all three inthomycins using Suzuki or Sonogashira couplings as key steps and a Kiyooka aldol to set the necessary asymmetry.

We envisaged that inthomycins A–C (1–3), could all be prepared through cross-coupling of the (*E*- or (*Z*)-alkenyl iodides 5 with the (*E,E*- or (*E,Z*)-dienylboronic esters 4 (Figure 2). The dienylboronic esters 4 were to be prepared by *syn* or *anti* hydroboration of the enyne oxazole 6 with the enyne oxazole 6 being prepared from alkylation of oxazole 8 with an electrophile derived from commercially available (*E*)-pent-2-en-4-yn-1-ol (7). The iodides 5 were to be prepared using an enantioselective Kiyooka aldol reaction^[14] between the silylketene acetal





Figure 2. Retrosynthesis of the inthomycins 1.

9 and the known (*E*- or (*Z*)-iodoaldehydes 10, which can be readily prepared from propargyl alcohol 11. This modular route allowed the ready synthesis of all three inthomycins A–C 1–3.

Our synthesis commenced with the preparation of the enyne oxazole 6 (Scheme 1). Commercially available (*E*)-pent-2-en-4-yn-1-ol 7^[15] was readily converted into the known bromide 12^[16] in two simple steps. After careful optimization we found that lithiation of the known silyl-protected oxazole 13^[17] with *n*-butyllithium followed by addition to CuCN·LiCl and addition of the bromide 12 gave the desired coupled product 14 in 81% yield.^[18]


The next stage in the synthesis involved the seemingly simple selective silyl group removal from 14 which proved unexpectedly challenging. Commonly used basic conditions for



Scheme 1. Synthesis of dienylboronic ester 15. a) *n*BuLi, Me₃SiCl, THF, –78 °C then 2 M HCl, 0 °C to RT, 62%; b) PPh₃, *N*-bromosuccinimide, CH₂Cl₂, –30 °C, 81%; c) *n*BuLi, *i*Pr₃SiOTf, THF, –78 °C to RT, 82%; d) 13, *n*BuLi, CuCN·2LiCl, THF, –78 °C then add 12, 81%; e) Na₂S, THF:H₂O (1:1), 0 °C to RT, 85%, after one recycle.; f) pinacol borane, (C₅H₅)₂ZrHCl, Et₃N, 60 °C, 84%. RT = room temperature, Tf = SO₂CF₃, THF = tetrahydrofuran.

trimethylsilyl group deprotection failed to give the desired product with allene formation being the major reaction pathway.^[19] The use of silver(I) salts to promote acetylene deprotection resulted in the formation of mixtures of starting material 14, the desired product 6, and fully desilylated material. Ultimately, we found that modifying Basak's procedure^[20] by using sodium sulfide in a mixture of THF and water, gave the desired mono-desilylated product 6 without allene formation although the reaction did not reach completion; the product 6 could be obtained in 85% yield after one recycle. Zirconium catalyzed hydroboration of the terminal acetylene in 6 gave the desired (*E,E*)-dienylboronic ester 15 in good yield and with complete stereocontrol.^[21]


The necessary Suzuki coupling partners for the dienylboronic ester 15 were prepared from the known (*Z*)- and (*E*)-iodoaldehydes (Z)-16 and (E)-16 (Scheme 2). Thus, propargyl alcohol 11



Scheme 2. Synthesis of the alkenyl iodides (*Z*)- and (*E*)-17. a) MeMgBr, Cu^I, THF, –10 °C then I₂, –10 to –5 °C, 66%; b) MnO₂, CH₂Cl₂; c) BH₃·THF, 18, 9, CH₂Cl₂, –78 °C then HCl, (Z)-5, 68% (2 steps), 89% ee, (E)-5, 61% (2 steps), 89% ee; d) Et₃SiCl, imidazole, CH₂Cl₂, 0 °C to RT, (Z)-17 93%, (E)-17 91%; e) Me₃Al, (C₅H₅)₂ZrCl₂, CH₂Cl₂, 0 °C to RT then I₂, –78 °C to RT, 61%.

was readily converted into the (*Z*)- and (*E*)-alkenyl iodides (Z)-16^[8,22] and (E)-16^[23] using Negishi's protocols. The (*Z*)- and (*E*)-alkenyl iodides (Z)-16 and (E)-16 were individually oxidized with manganese dioxide to the corresponding aldehydes 10 and subjected to the enantioselective Mukaiyama aldol reaction developed by Kiyooka^[14] using the ketene acetal 9 in the presence of *L*-*N*-tosylvaline (18).^[24] This gave the corresponding aldols (Z)-5 (68% yield, 94.5:5.5 er) and (E)-5 (61% yield, 94.5:5.5 er) which were converted into the corresponding silyl ethers (Z)-17 and (E)-17 under standard conditions.

Having established reliable routes to both the dienylboronic ester 15 and the two alkenyl iodides (Z)-17 and (E)-17, we next addressed the key Suzuki coupling reaction (Scheme 3).^[25] After extensive experimentation we found that the use of palladium(II) acetate and triphenylphosphine in the presence of 1 M aqueous sodium bicarbonate allowed the union of the dienylboronic ester 15 with the (*Z*)-alkenyl iodide (Z)-17 to proceed with complete stereochemical fidelity to give the corresponding coupled product 19 in 64% yield. Double deprotection of the triene 19 with HF in acetonitrile^[9] gave the alcohol 20 which was converted into inthomycin B 2 via aminolysis of the corresponding pentafluorophenyl ester 21. Our synthetic



Scheme 3. Synthesis of inthomycins B and C. a) (*Z*)-17 or (*E*)-17, Pd(OAc)₂, PPh₃, Na₂CO₃, THF, H₂O, **19** 64%, **22** 65%; b) HF-pyridine, CH₃CN, 0 °C to RT, **20** 80%, **23** 97%; c) LiOH, H₂O, THF, MeOH, 0 °C to RT; d) C₆H₅OH, EDCI-HCl, DMAP, CH₂Cl₂, **21** 80% (2 steps), **24** 87% (2 steps); e) NH₄OH, THF, 0 °C to RT, **2** 95%, **3** 94%. EDCI = 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide).


inthomycin B **2** had spectroscopic properties in accord with that of both natural and synthetic inthomycin B **2**.

For the synthesis of inthomycin C **3**, the Suzuki coupling between the (*Z,Z*)-dienyl boronate **15** and the (*E*)-alkenyl iodide (*E*)-17 required further optimization. Ultimately, we found that the concentration of aqueous base proved crucial with the use of 0.25 M sodium bicarbonate giving the coupled product **22** in 65% yield. In a similar manner to the synthesis of inthomycin B **2**, inthomycin C **3** was prepared from the triene **22** by the same reaction sequence. Our synthetic inthomycin C **3** had spectroscopic properties in accord with that of both natural and synthetic inthomycin C **3**.

Having successfully synthesized inthomycins B **2** and C **3** we turned our attention to inthomycin A **1** (Scheme 4). We had originally aimed to prepare inthomycin A **1** by the same strategy namely Suzuki cross-coupling of a (*Z,E*)-dienylboronic acid (*Z,E*)-15, however, rhodium(I) catalyzed anti-selective hydroboration^[26] of the enyne **6** gave the corresponding (*Z,E*)-dienylboronic ester (*Z,E*)-15 in low yields (<40%) under a number of conditions. We therefore altered our synthetic strategy and investigated a Sonogashira/semi-hydrogenation sequence. Pleasingly, the Sonogashira reaction of the alkenyl iodide (*Z*)-17 with the enyne **6** proceeded smoothly under standard conditions to give the coupled product **25** in 62% yield. The next challenge was the semi-hydrogenation of the alkyne to give the (*Z,Z,E*)-triene required for completion of the synthesis of inthomycin A. Semi-hydrogenation of **25** under a variety of con-

ditions [Pd, CaCO₃, quinoline; Pd, CaCO₃; Pd, BaSO₄; nickel boride; Zn (Cu/Ag)] gave mixtures of the desired product, over reduced products and starting material and we were unable to isolate the desired triene in synthetically useful yields. We therefore investigated the semi-hydrogenation of the alcohol **26** formed by double deprotection of **25**. Pleasingly the use of Zn(Cu/Ag) couple in methanol at above room temperature gave the desired (*Z,Z,E*)-triene **27** in 80% yield.^[27] As before, the methyl ester **27** was readily transformed into the corresponding amide target inthomycin A **1** via the pentafluorophenyl ester **28**. Careful analysis of the ¹H and ¹³C NMR spectra of **1** indicated that it was contaminated with a small amount (<10%) of inthomycin B **2** which appears to arise during conversion of the ester **27** into inthomycin A **1**.

All of our synthesized inthomycins had spectroscopic properties in accord with the natural and previously synthesized compounds. Importantly, the absolute configuration of inthomycin C **1** has been the subject of much confusion and debate in the literature. However, recently these ambiguities have been laid to rest by Hale and Hatakeyama^[13b] with the absolute configuration of inthomycin C **1** being firmly established as (*R*) confirming the original assignment by Henkel and Zeek.^[3] We had assigned the absolute configuration of the alkenyl iodides (*Z*)-5 and (*E*)-5 as



Scheme 4. Synthesis of inthomycin A. a) (*Z*)-17, Pd(PPh₃)₄, CuI, Et₃N, 62%; b) HF-pyridine, CH₃CN, 0 °C to RT, 91%; c) Zn-Cu-Ag couple, MeOH, 35 °C, 80%; d) LiOH, H₂O, THF, MeOH, 0 °C to RT; e) C₆H₅OH, EDCI-HCl, DMAP, CH₂Cl₂, 78% (2 steps); f) NH₄OH, THF, 0 °C to RT, 89%.

(*S*) using Kakisawa's extension of Mosher's method^[28] which translates into the absolute configuration of all of the inthomycins being (*R*), and our optical rotation for **3** was in agreement with the recently remeasured values.^[13b]

In summary, we have developed efficient modular enantioselective total syntheses of all three inthomycins, which proceeds

in only 9/10 steps from commercially available materials. The key steps include Suzuki and Sonogashira cross-couplings, and an enantioselective Kiyooka aldol reaction. Our modular route has allowed the efficient syntheses of these biologically active natural products and we will use this synthetic sequence in our assault on the synthesis of the oxazolomycins.###

Acknowledgements

We thank the EPSRC and the European Union (H2020-MSCA-IF-2015-708354) for funding this work.

Conflict of interest

The authors declare no conflict of interest.

Keywords: inthomycin · phtoxazolin · total synthesis

- [1] S. Ōmura, Y. Tanaka, I. Kanaya, M. Shinose, Y. Takahashi, *J. Antibiot.* **1990**, *43*, 1034–1036.
- [2] K. Shiomi, N. Arai, M. Shinose, Y. Takahashi, H. Yoshida, J. Iwabuchi, Y. Tanaka, S. Ōmura, *J. Antibiot.* **1995**, *48*, 714–719.
- [3] T. Henkel, A. Zeeck, *Liebigs Ann. Chem.* **1991**, 367–373.
- [4] Y. Tanaka, I. Kanaya, Y. Takahashi, M. Shinose, H. Tanaka, S. Ōmura, *J. Antibiot.* **1993**, *46*, 1208–1213.
- [5] S. Ōmura, *Gene* **1992**, *115*, 141–149.
- [6] a) M. Kawada, Y. Yosshimoto, K. Minaniguchi, H. Kumagai, T. Someno, T. Masuda, M. Ishizuka, D. Ikeda, *Anticancer Res.* **2004**, *24*, 1561–1568; b) M. Kawada, H. Inoue, I. Usami, D. Ikeda, *Cancer Sci.* **2009**, *100*, 150–157.
- [7] S. Balcells, M. B. Haughey, J. C. L. Walker, L. Josa-Cullere, C. Towers, T. J. Donohoe, *Org. Lett.* **2018**, *20*, 3583–3586.
- [8] a) N. Hénaff, A. Whiting, *Org. Lett.* **1999**, *1*, 1137–1139; b) N. Hénaff, A. Whiting, *Tetrahedron* **2000**, *56*, 5193–5204.
- [9] M. Yoshino, K. Eto, K. Takahashi, J. Ishihara, S. Hatakeyama, *Org. Biomol. Chem.* **2012**, *10*, 8164–8174.
- [10] M. R. Webb, C. Donald, R. J. K. Taylor, *Tetrahedron Lett.* **2006**, *47*, 549–552.
- [11] M. R. Webb, M. S. Addie, C. M. Crawforth, J. W. Dale, X. Franci, M. Pizzonero, C. Donald, R. J. K. Taylor, *Tetrahedron* **2008**, *64*, 4778–4791.
- [12] B. K. Senapati, L. Gao, S. I. Lee, G.-S. Hwang, D. H. Ryu, *Org. Lett.* **2010**, *12*, 5088–5091.
- [13] a) K. J. Hale, M. Grabski, S. Manaviazar, M. Maczka, *Org. Lett.* **2014**, *16*, 1164–1167; b) K. J. Hale, S. Hatakeyama, F. Urabe, J. Ishihara, S. Manaviazar, M. Grabski, M. Maczka, *Org. Lett.* **2014**, *16*, 3536–3539.
- [14] S. Kiyooka, Y. Kaneko, M. Komura, H. Matsuo, M. Nakano, *J. Org. Chem.* **1991**, *56*, 2276–2278.
- [15] (*E*)-Pent-2-en-4-yn-1-ol can be readily prepared in 1 step from epichlorohydrin and metal acetylides see for example: D. Holland, J. F. Stoddart, *J. Chem. Soc. Perkin Trans. 1* **1983**, 1553–1571.
- [16] K. C. Nicolaou, C. A. Veale, S. E. Webber, H. Katerinopoulos, *J. Am. Chem. Soc.* **1985**, *107*, 7515–7518.
- [17] a) R. A. Miller, R. M. Smith, S. Karady, R. A. Reamer, *Tetrahedron Lett.* **2002**, *43*, 935–938; b) R. A. Miller, R. M. Smith, B. Marcune, *J. Org. Chem.* **2005**, *70*, 9074–9076.
- [18] a) For metallation (tBuLi, then CuCN) and alkylation of 2-(*n*-butylthio)oxazole with various electrophiles including **12** see: J. P. Marino, H. N. Nguyen, *Tetrahedron Lett.* **2003**, *44*, 7395–7398; b) For allylation of **13** using *n*BuLi, CuCN and allyl bromide see Ref. [7].
- [19] For an example of allene formation during deprotection of a silylated enyne see: A. B. Holmes, C. L. D. Jennings-White, D. A. Kendrick, *J. Chem. Soc. Chem. Commun.* **1984**, 1594–1595.
- [20] I. Hatial, R. Mukherjee, K. Senapati, A. Basak, *Tetrahedron Lett.* **2015**, *56*, 4275–4279.
- [21] S. Pereira, M. Srebnik, *Organometallics* **1995**, *14*, 3127–3128.
- [22] M. Kotor, E. Negishi, *Synthesis* **1997**, 121–128.
- [23] G. Wang, E. I. Negishi, *Eur. J. Org. Chem.* **2009**, 1679–1682.
- [24] For previous uses of the Kiyooka aldol reaction in the synthesis of the inthomycins see ref. [7, 10, 11].
- [25] N. Miyaura, A. Suzuki, *Chem. Rev.* **1995**, *95*, 2457–2483.
- [26] T. Ohmura, Y. Yamamoto, N. Miyaura, *J. Am. Chem. Soc.* **2000**, *122*, 4990–4991.
- [27] B. Wilhelm, S. Nora, S. Christiane, F. Martin, *Helv. Chim. Acta* **1987**, *70*, 1025–1040.
- [28] a) I. Ohtani, T. Kusumi, Y. Kashman, H. Kakisawa, *J. Am. Chem. Soc.* **1991**, *113*, 4092–4096; b) T. R. Hoye, C. S. Jeffrey, F. Shao, *Nat. Protoc.* **2007**, *2*, 2451–2458.

Manuscript received: July 24, 2018
Version of record online: October 19, 2018